Celgene和Innovent与Adimab签署治疗性抗体合作

Adimab公司8月20日宣布，已与赛尔基因（Celgene）签署了一项多靶标发现合作。根据协议，Adimab将利用其专有的抗体发现和优化平台，针对Celgene所提供的数个靶标生产治疗性抗体。Celgene将有权开发和商业化此次合作中所产生的所有治疗性抗体。

Adimab同时宣布，已与Innovent制药就一种治疗性抗体项目的发现、开发和商业化达成了一项新的合作伙伴关系。根据协议，Adimab将利用其抗体发现和优化平台，针对Innovent所选的一种靶标，鉴别一种全人源化治疗性抗体。

此外，Adimab还宣布，与礼来（Eli Lilly）、吉利德（Gilead）、协和发酵麒麟（Kyowa Hakko Kirin）之间的合作已取得技术里程碑。

Adimab的酵母抗体平台，是一个及其灵活的抗体发现和工程化工具，能够应用于各种不同治疗开发方法，包括IgG的发现、优化、人源化及双特异性（bispecifics）。

过去4年里，Adimab已经与多个制药巨头达成合作，包括默沙东（Merck & Co）、罗氏（Roche）、诺华（Novartis）、礼来（Eli Lilly）、罗氏旗下基因泰克（Genentech）、百健艾迪（Biogen Idec）、诺和诺德（Novo Nordisk）、吉利德（Gilead）、协和发酵麒麟（Kyowa Hakko Kirin）、葛兰素史克（GSK）。

Adimab的整合抗体发现及优化平台，从抗原至获得纯化的全长人类IgGs整个流程，提供了前所未有的速度。该平台，通过提供多样化的治疗相关抗体，能够满足亲和力、抗原表位覆盖、物种交叉反应、开发能力各方面最为严格的标准，提供了根本性的优势。通过广泛的技术获取协议，Adimab有能力使合作伙伴迅速扩展其生物制剂管线.

Adimab Announces New Antibody Discovery Collaboration with Celgene Corporation

08/20/2013 | 08:35am US/Eastern

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced a multi-target discovery collaboration with Celgene Corporation of Summit, NJ. Under terms of the Agreement, Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets. Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

"We are very pleased to announce another major pharma partnership," said Tillman Gerngross, CEO and co-founder of Adimab. "Celgene has developed a highly successful oncology and inflammation franchise, and we are excited to partner with them to support their expanding antibody-based therapeutic portfolio."

Adimab and Celgene have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets. For each target, the Agreement grants Celgene the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the Agreement, Adimab will receive an undisclosed upfront payment. In addition, for each target, Celgene will have the option to exclusively license antibodies generated during the collaboration. If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales.

"The speed and technical superiority of our platform drives all of our deal flow," said Guy Van Meter, Vice President of Business Development at Adimab. "The Adimab Platform is an extremely versatile antibody discovery and engineering tool that can be applied to a variety of different therapeutic development approaches, including IgG discovery, optimization, humanization and bispecifics."

Over the past four years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK.

About Adimab

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.